These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 36621213)

  • 21. Effects of metformin, insulin on COVID-19 patients with pre-existed type 2 diabetes: A multicentral retrospective study.
    Cheng X; Xin S; Chen Y; Li L; Chen W; Li W; Zhou B; Li C; Gong Y; Li F; Duan P; Zhou X
    Life Sci; 2021 Jun; 275():119371. PubMed ID: 33745895
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A review on protective roles and potential mechanisms of metformin in diabetic patients diagnosed with COVID-19.
    Kifle ZD; Woldeyohanis AE; Demeke CA
    Metabol Open; 2021 Dec; 12():100137. PubMed ID: 34664036
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is there an association between metformin use and clinical outcomes in diabetes patients with COVID-19?
    Do JY; Kim SW; Park JW; Cho KH; Kang SH
    Diabetes Metab; 2021 Jul; 47(4):101208. PubMed ID: 33160030
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metformin as a potential treatment for COVID-19.
    MCCarthy MW
    Expert Opin Pharmacother; 2023; 24(10):1199-1203. PubMed ID: 37194484
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Extremely high-dose insulin requirement in a diabetic patient with COVID-19: a case report.
    Jornayvaz FR; Assouline B; Pugin J; Gariani K
    BMC Endocr Disord; 2020 Oct; 20(1):155. PubMed ID: 33066762
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Factors leading to high morbidity and mortality of COVID-19 in patients with type 2 diabetes.
    Rajpal A; Rahimi L; Ismail-Beigi F
    J Diabetes; 2020 Dec; 12(12):895-908. PubMed ID: 32671936
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inpatient use of metformin and acarbose is associated with reduced mortality of COVID-19 patients with type 2 diabetes mellitus.
    Li J; Wei Q; McCowen KC; Xiong W; Liu J; Jiang W; Thomas RL; Hepokoski M; He M; Shyy JYJ; Malhotra A; Xiong N; Li WX
    Endocrinol Diabetes Metab; 2022 Jan; 5(1):e00301. PubMed ID: 34585841
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metformin to decrease COVID-19 severity and mortality: Molecular mechanisms and therapeutic potential.
    Kamyshnyi O; Matskevych V; Lenchuk T; Strilbytska O; Storey K; Lushchak O
    Biomed Pharmacother; 2021 Dec; 144():112230. PubMed ID: 34628168
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is metformin a miracle or a menace in COVID-19 patients with type 2 diabetes?
    Lui DTW; Tan KCB
    J Diabetes Investig; 2021 Apr; 12(4):479-481. PubMed ID: 33331120
    [TBL] [Abstract][Full Text] [Related]  

  • 30. COVID-19 in diabetic patients: Related risks and specifics of management.
    Orioli L; Hermans MP; Thissen JP; Maiter D; Vandeleene B; Yombi JC
    Ann Endocrinol (Paris); 2020 Jun; 81(2-3):101-109. PubMed ID: 32413342
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gene expression of protein kinase AMP-activated catalytic subunit alpha 1 (PRKAA1), solute carrier family 2 member 1 (SLC2A1) and mechanistic target of rapamycin (MTOR) in metformin-treated type 2 diabetes patients with COVID-19: impact on inflammation markers.
    Petakh P; Kamyshna I; Kamyshnyi A
    Inflammopharmacology; 2024 Feb; 32(1):885-891. PubMed ID: 37773574
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cancer vs. SARS-CoV-2 induced inflammation, overlapping functions, and pharmacological targeting.
    Amere Subbarao S
    Inflammopharmacology; 2021 Apr; 29(2):343-366. PubMed ID: 33723711
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metformin Use in Relation to Clinical Outcomes and Hyperinflammatory Syndrome Among COVID-19 Patients With Type 2 Diabetes: A Propensity Score Analysis of a Territory-Wide Cohort.
    Wong CKH; Lui DTW; Lui AYC; Low MCH; Kwok ACY; Lau KTK; Au ICH; Xiong X; Chung MSH; Lau EHY; Cowling BJ
    Front Endocrinol (Lausanne); 2022; 13():810914. PubMed ID: 35321338
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-inflammatory properties of antidiabetic drugs: A "promised land" in the COVID-19 era?
    Katsiki N; Ferrannini E
    J Diabetes Complications; 2020 Dec; 34(12):107723. PubMed ID: 32900588
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metformin Treatment Was Associated with Decreased Mortality in COVID-19 Patients with Diabetes in a Retrospective Analysis.
    Luo P; Qiu L; Liu Y; Liu XL; Zheng JL; Xue HY; Liu WH; Liu D; Li J
    Am J Trop Med Hyg; 2020 Jul; 103(1):69-72. PubMed ID: 32446312
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Efficacy and Potential Mechanisms of Metformin in the Treatment of COVID-19 in the Diabetics: A Systematic Review.
    Zangiabadian M; Nejadghaderi SA; Zahmatkesh MM; Hajikhani B; Mirsaeidi M; Nasiri MJ
    Front Endocrinol (Lausanne); 2021; 12():645194. PubMed ID: 33815295
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of Diabetes in Patients Diagnosed With COVID-19.
    Abu-Farha M; Al-Mulla F; Thanaraj TA; Kavalakatt S; Ali H; Abdul Ghani M; Abubaker J
    Front Immunol; 2020; 11():576818. PubMed ID: 33335527
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diabetes and coronavirus (SARS-CoV-2): Molecular mechanism of Metformin intervention and the scientific basis of drug repurposing.
    Varghese E; Samuel SM; Liskova A; Kubatka P; Büsselberg D
    PLoS Pathog; 2021 Jun; 17(6):e1009634. PubMed ID: 34157054
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The epidemiology, pathophysiological mechanisms, and management toward COVID-19 patients with Type 2 diabetes: A systematic review.
    Yin Y; Rohli KE; Shen P; Lu H; Liu Y; Dou Q; Zhang L; Kong X; Yang S; Jia P
    Prim Care Diabetes; 2021 Dec; 15(6):899-909. PubMed ID: 34600859
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diabetes mellitus and COVID-19: review of a lethal interaction from the cellular and molecular level to the bedside.
    Ali Kazem T; Zeylabi F; Filayih Hassan A; Paridar P; Pezeshki SP; Pezeshki SMS
    Expert Rev Endocrinol Metab; 2022 Jan; 17(1):1-19. PubMed ID: 34781797
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.